(UroToday.com) The NIVOREN GETUF AFU 26 study is a French multi-center prospective study to evaluate the safety and efficacy of the anti-PD-1 checkpoint agent nivolumab in a “real world” setting after failure of 1-2 tyrosine kinase inhibitor in metastatic renal cell carcinoma (mRCC). As antibiotic use around the time of starting immune checkpoint blockade has been associated with reduced efficacy in multiple cancer types, Dr. Derosa and colleagues identified patients from the NIVOREN study who received antibiotics between 60 days prior to starting therapy to 42 days after starting nivolumab and assessed the impact on clinical outcomes and toxicities.